AG-QUETIAPINE XR TABLET (EXTENDED-RELEASE)
国: カナダ
言語: 英語
ソース: Health Canada
製品の特徴
(SPC)
20-09-2021
この製品の一部のドキュメントは現在利用できません。カスタマーサービスにリクエストを送信できます。入手可能になり次第、お知らせします。
リクエストを送信します。
リクエストを送信します。
有効成分:
QUETIAPINE (QUETIAPINE FUMARATE)
から入手可能:
ANGITA PHARMA INC.
ATCコード:
N05AH04
INN（国際名）:
QUETIAPINE
投薬量:
200MG
医薬品形態:
TABLET (EXTENDED-RELEASE)
構図:
QUETIAPINE (QUETIAPINE FUMARATE) 200MG
投与経路:
ORAL
パッケージ内のユニット:
15G/50G
処方タイプ:
Prescription
治療領域:
ATYPICAL ANTIPSYCHOTICS
製品概要:
Active ingredient group (AIG) number: 0131858003; AHFS:
認証ステータス:
APPROVED
承認日:
2021-09-21
製品の特徴
PRODUCT MONOGRAPH
PR
AG-QUETIAPINE XR
Quetiapine Fumarate Extended-Release Tablets
50 mg, 150 mg, 200 mg, 300 mg and 400 mg quetiapine (as quetiapine
fumarate)
House Standard
Antipsychotic / Antidepressant Agent
Angita Pharma Inc.
Date of Preparation:
1310 rue Nobel
September 20, 2021
Boucherville, Québec
J4B 5H3, Canada
Submission Control No: 255711
Product Monograph of AG-Quetiapine XR
Page 2 of 79
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
................................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
4
ADVERSE REACTIONS
.........................................................................................................
17
DRUG INTERACTIONS
.........................................................................................................
37
DOSAGE AND ADMINISTRATION
.....................................................................................
39
OVERDOSAGE
........................................................................................................................
43
ACTION AND CLINICAL PHARMACOLOGY
....................................................................
44
STORAGE AND STABILITY
.................................................................................................
47
DOSAGE FORMS, COMPOSITION AND PACKAGING
..................................................... 47
PART II: SCIENTIFIC INFORMATION
...............................................................................48
PHARMACEUTICAL INFORMATION
.................................................................................
完全なドキュメントを読む
